RESEARCH TRIANGLE PARK, N.C., July 22 /PRNewswire-FirstCall/ --
Biotechnology company Icoria, Inc. (OTCBB: ICOR.OB) today announced that Anna
Mae Diehl, M.D. has joined its Scientific Advisory Board. Dr. Diehl is Chief
of the Division of Gastroenterology at Duke University and Director of the
Duke Liver Center and is nationally recognized as an expert in basic research
and clinical treatment for chronic liver disease.
"We are extremely pleased that Dr. Diehl has agreed to join our scientific
advisory board," said Thomas Colatsky, Ph.D., Icoria's Chief Scientific
Officer. "Dr. Diehl's experience in chronic liver disease at both the bench
and bedside will be invaluable to Icoria as we seek to develop new diagnostic
panels to monitor disease state and patient response."
In her role as an Icoria advisor, Dr. Diehl will provide expert guidance
to Icoria's biomarker discovery team as they develop new diagnostic approaches
to liver injury and chronic liver disease. Dr. Diehl joins a distinguished
board, which also includes Michael L. McCaleb, Ph.D., Paul Watkins, M.D., and
Michael N. Liebman, Ph.D.
Dr. Diehl's research interests include the cause and treatment of
nonalcoholic fatty liver disease, frequently seen as a complication of obesity
or diabetes, both therapeutic areas currently being studied at Icoria. Her
basic research focuses on mouse models of disease and the molecular regulation
of liver injury and repair. She is the principal investigator at the Duke site
for the multi-center NASH (nonalcoholic steatohepatitis) treatment trial for
nonalcoholic fatty liver disease, which is presently recruiting patients.
Prior to joining Duke in 2004, Dr. Diehl was Director of the Hepatology
Section at Johns Hopkins University, where she held the Moses and Helen Golden
Paulson Professorship of Gastroenterology. In 2001, she received the Leon
Schiff Prize for outstanding research in clinical liver disease from the
American Association for the Study of Liver Diseases and was awarded the Hans
Popper Prize for outstanding basic liver research from the International
Association for the Study of Liver Diseases in 2002.
Icoria's Scientific Advisory Board provides a link between Icoria and the
academic, medical and scientific community. Board members advise the company
on its research and development programs and represent a valued independent
resource. Biographical information on members of Icoria's Scientific Advisory
Board is available at http://www.Icoria.com.
About Icoria
Icoria, Inc. is a biotechnology company focused on the discovery of novel,
multi-parameter biomarkers using its unique multi-platform approach. Icoria
intends to use these future biomarkers internally to develop multi-analyte
diagnostics to define and grade pathology or disease state with a high level
of specificity and sensitivity, and use its technology to help collaborators
and customers develop better, safer drugs and diagnostics and to identify
targets, leads and drug/diagnostic combinations for liver injury, metabolic
disorders and cancer. Icoria's shares trade on the over the counter bulletin
board.
This press release contains forward-looking statements including, but not
limited to, the Company's expectations for its healthcare based business model
and its biomarker discovery platform. Such forward-looking statements are
based on management's current expectations and are subject to a number of
risks, factors and uncertainties that may cause actual results, events and
performance to differ materially from those referred to in the forward-looking
statements. These risks, factors and uncertainties include, but are not
limited to, Icoria's ability to identify biomarkers, early stage of
development, history of net losses, technological and product development
uncertainties, reliance on research collaborations, uncertainty of additional
funding and ability to protect its patents and proprietary rights. Certain of
these and other risks are identified in Icoria's Quarterly Report on Form 10-Q
for the period ended March 31, 2005, as amended, and its Annual Report on Form
10-K for the year ended December 31, 2004, both as filed with the Securities
and Exchange Commission. The Company does not intend to update any of the
forward-looking statements after the date of this release to conform these
statements to actual results or to changes in our expectations, except as may
be required by law.
SOURCE Icoria, Inc.
 back to top
Related links:
http://www.icoria.com
CONTACT:
Media-Public Relations of Icoria, Inc.,
+1-919-425-2999
|
